Among 1,030 patients with mild to moderate COVID-19 cases, researchers tested the efficacy of 125 milligram and 250 milligram solutions of ensitrelvir compared to a placebo. All of the study participants received treatments within the first three days of symptom onset.
The biggest finding was the 125 milligram dose, which cut symptom duration by 24.3 hours compared to the placebo. The results from the study, which was conducted in 2022, were published Feb. 9 in JAMA.
The FDA is still reviewing ensitrelvir as a possible COVID-19 treatment.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
